Ellen Burnham
Concepts (558)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 39 | 2025 | 830 | 6.370 |
Why?
| | Respiratory Insufficiency | 11 | 2026 | 330 | 2.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 641 | 1.890 |
Why?
| | Intensive Care Units | 21 | 2025 | 923 | 1.790 |
Why?
| | Lung | 19 | 2025 | 4119 | 1.660 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 125 | 1.590 |
Why?
| | Cannabis | 5 | 2025 | 519 | 1.260 |
Why?
| | Pneumonia | 9 | 2023 | 633 | 1.250 |
Why?
| | Ethanol | 11 | 2022 | 629 | 1.220 |
Why?
| | Acute Lung Injury | 10 | 2022 | 311 | 1.200 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 323 | 1.180 |
Why?
| | Critical Illness | 21 | 2024 | 905 | 1.110 |
Why?
| | Marijuana Smoking | 3 | 2025 | 248 | 1.070 |
Why?
| | Hospitalization | 10 | 2025 | 2468 | 1.050 |
Why?
| | Sepsis | 6 | 2020 | 668 | 1.010 |
Why?
| | Gene Expression | 3 | 2020 | 1461 | 0.990 |
Why?
| | Patient Admission | 2 | 2025 | 216 | 0.970 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 377 | 0.960 |
Why?
| | Cytokines | 9 | 2025 | 2079 | 0.930 |
Why?
| | Middle Aged | 76 | 2026 | 36359 | 0.910 |
Why?
| | Critical Care | 10 | 2021 | 700 | 0.890 |
Why?
| | Survivors | 8 | 2025 | 521 | 0.860 |
Why?
| | Inflammation Mediators | 4 | 2016 | 507 | 0.850 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 83 | 0.800 |
Why?
| | Adult | 69 | 2025 | 40821 | 0.800 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 385 | 0.800 |
Why?
| | Acetates | 2 | 2021 | 78 | 0.790 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 66 | 0.780 |
Why?
| | Stem Cells | 5 | 2015 | 612 | 0.770 |
Why?
| | Humans | 134 | 2026 | 145625 | 0.760 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 187 | 0.750 |
Why?
| | Smoking | 8 | 2021 | 1478 | 0.750 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 395 | 0.740 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 184 | 0.730 |
Why?
| | Mentors | 4 | 2014 | 215 | 0.730 |
Why?
| | Hospital Mortality | 7 | 2025 | 1037 | 0.730 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 585 | 0.720 |
Why?
| | Lung Diseases | 3 | 2021 | 787 | 0.710 |
Why?
| | Male | 84 | 2026 | 73014 | 0.700 |
Why?
| | Female | 86 | 2026 | 79080 | 0.690 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 293 | 0.670 |
Why?
| | Behavior | 1 | 2021 | 90 | 0.640 |
Why?
| | Thalamus | 2 | 2021 | 132 | 0.630 |
Why?
| | Glycerophospholipids | 4 | 2024 | 39 | 0.630 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 221 | 0.630 |
Why?
| | Case-Control Studies | 14 | 2022 | 3633 | 0.620 |
Why?
| | Respiration, Artificial | 13 | 2025 | 711 | 0.620 |
Why?
| | Burns | 5 | 2025 | 365 | 0.600 |
Why?
| | Burnout, Professional | 4 | 2022 | 489 | 0.600 |
Why?
| | Hallucinogens | 1 | 2021 | 112 | 0.580 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1098 | 0.580 |
Why?
| | Cigarette Smoking | 2 | 2020 | 103 | 0.570 |
Why?
| | Glutathione | 5 | 2016 | 369 | 0.550 |
Why?
| | Antioxidants | 4 | 2016 | 544 | 0.550 |
Why?
| | RNA, Messenger | 5 | 2020 | 2783 | 0.550 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 48 | 0.540 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 125 | 0.530 |
Why?
| | Tobacco Products | 1 | 2019 | 90 | 0.530 |
Why?
| | Epithelial Cells | 4 | 2021 | 1118 | 0.530 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 24 | 0.520 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 328 | 0.520 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 611 | 0.520 |
Why?
| | Physicians, Women | 1 | 2019 | 91 | 0.520 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 90 | 0.510 |
Why?
| | Inflammation | 8 | 2025 | 2915 | 0.510 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 277 | 0.480 |
Why?
| | Biomedical Research | 2 | 2021 | 724 | 0.480 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 11 | 0.470 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 55 | 0.470 |
Why?
| | Aged | 36 | 2026 | 26251 | 0.460 |
Why?
| | Marijuana Abuse | 1 | 2018 | 215 | 0.460 |
Why?
| | Alcohol Drinking | 6 | 2025 | 847 | 0.450 |
Why?
| | Biomarkers | 16 | 2026 | 4329 | 0.450 |
Why?
| | Retrospective Studies | 25 | 2025 | 17291 | 0.440 |
Why?
| | Azithromycin | 1 | 2015 | 101 | 0.430 |
Why?
| | Tomography | 2 | 2025 | 44 | 0.420 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 926 | 0.420 |
Why?
| | Electric Impedance | 2 | 2025 | 108 | 0.420 |
Why?
| | Research Support as Topic | 2 | 2011 | 81 | 0.400 |
Why?
| | Professional Autonomy | 1 | 2013 | 29 | 0.400 |
Why?
| | Hypoxia | 4 | 2026 | 1209 | 0.400 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 174 | 0.390 |
Why?
| | Cells, Cultured | 8 | 2018 | 4112 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2766 | 0.380 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 861 | 0.380 |
Why?
| | Bronchoscopy | 3 | 2023 | 227 | 0.380 |
Why?
| | Oxidative Stress | 5 | 2017 | 1367 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2018 | 843 | 0.370 |
Why?
| | Asthma | 2 | 2022 | 1800 | 0.360 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 24 | 0.350 |
Why?
| | Academic Medical Centers | 2 | 2014 | 560 | 0.330 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 293 | 0.330 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 578 | 0.330 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 330 | 0.320 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2591 | 0.320 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.300 |
Why?
| | Malondialdehyde | 2 | 2021 | 31 | 0.300 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.300 |
Why?
| | United States | 18 | 2026 | 16041 | 0.300 |
Why?
| | Muscular Diseases | 3 | 2017 | 110 | 0.300 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 100 | 0.300 |
Why?
| | Personnel Selection | 1 | 2011 | 90 | 0.300 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 80 | 0.300 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 104 | 0.290 |
Why?
| | Cohort Studies | 13 | 2020 | 6045 | 0.280 |
Why?
| | Smokers | 2 | 2021 | 139 | 0.280 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 122 | 0.280 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1935 | 0.280 |
Why?
| | Prevalence | 4 | 2025 | 2852 | 0.280 |
Why?
| | Epidemics | 2 | 2019 | 97 | 0.260 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.260 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 245 | 0.260 |
Why?
| | Airway Extubation | 3 | 2013 | 60 | 0.260 |
Why?
| | Sexism | 2 | 2019 | 70 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.250 |
Why?
| | Benzodiazepines | 2 | 2025 | 156 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1223 | 0.250 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 7 | 0.250 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 193 | 0.250 |
Why?
| | Naltrexone | 2 | 2025 | 114 | 0.250 |
Why?
| | Pilot Projects | 6 | 2025 | 1878 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1531 | 0.250 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.240 |
Why?
| | Fibronectins | 1 | 2007 | 136 | 0.240 |
Why?
| | Deglutition Disorders | 3 | 2013 | 159 | 0.240 |
Why?
| | APACHE | 4 | 2013 | 67 | 0.240 |
Why?
| | Endothelial Cells | 4 | 2011 | 876 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1370 | 0.240 |
Why?
| | Young Adult | 13 | 2024 | 14240 | 0.230 |
Why?
| | Marijuana Use | 2 | 2022 | 218 | 0.230 |
Why?
| | Administration, Inhalation | 3 | 2025 | 567 | 0.230 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 167 | 0.230 |
Why?
| | Immunity, Cellular | 2 | 2018 | 277 | 0.230 |
Why?
| | Preoperative Care | 1 | 2008 | 375 | 0.230 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 7 | 0.230 |
Why?
| | Risk Factors | 16 | 2020 | 10840 | 0.220 |
Why?
| | Anesthesiology | 1 | 2008 | 178 | 0.220 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 28 | 0.220 |
Why?
| | Pediatrics | 1 | 2013 | 1122 | 0.220 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 57 | 0.220 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1212 | 0.220 |
Why?
| | Arachidonic Acids | 1 | 2025 | 42 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 379 | 0.220 |
Why?
| | Flow Cytometry | 2 | 2024 | 1160 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 53 | 0.210 |
Why?
| | Propofol | 1 | 2025 | 86 | 0.210 |
Why?
| | Endocannabinoids | 1 | 2025 | 55 | 0.210 |
Why?
| | tau Proteins | 1 | 2025 | 111 | 0.210 |
Why?
| | Dysbiosis | 2 | 2024 | 184 | 0.210 |
Why?
| | Immunity | 1 | 2025 | 140 | 0.210 |
Why?
| | E-Selectin | 1 | 2004 | 61 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 880 | 0.200 |
Why?
| | Bacterial Proteins | 1 | 2010 | 976 | 0.200 |
Why?
| | Quality of Life | 2 | 2013 | 3187 | 0.200 |
Why?
| | Patient Discharge | 3 | 2024 | 991 | 0.200 |
Why?
| | Immunophenotyping | 1 | 2024 | 324 | 0.190 |
Why?
| | Interleukin-1beta | 2 | 2017 | 394 | 0.190 |
Why?
| | Central Nervous System | 1 | 2025 | 278 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2025 | 290 | 0.190 |
Why?
| | Narcotic Antagonists | 1 | 2025 | 209 | 0.190 |
Why?
| | Anticoagulants | 2 | 2019 | 743 | 0.190 |
Why?
| | Aged, 80 and over | 10 | 2022 | 8351 | 0.190 |
Why?
| | Shock, Septic | 2 | 2022 | 230 | 0.190 |
Why?
| | Internship and Residency | 1 | 2013 | 1269 | 0.190 |
Why?
| | Interferons | 2 | 2016 | 186 | 0.190 |
Why?
| | Dyspnea | 2 | 2019 | 251 | 0.190 |
Why?
| | Polyneuropathies | 2 | 2017 | 57 | 0.180 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 22 | 0.180 |
Why?
| | Lung Injury | 2 | 2016 | 262 | 0.180 |
Why?
| | Epithelium | 2 | 2021 | 295 | 0.180 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 29 | 0.170 |
Why?
| | Age Factors | 4 | 2021 | 3321 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 440 | 0.170 |
Why?
| | Interleukin-8 | 3 | 2018 | 268 | 0.170 |
Why?
| | Delirium | 1 | 2023 | 106 | 0.170 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 13 | 0.170 |
Why?
| | Fibroblasts | 3 | 2013 | 1033 | 0.170 |
Why?
| | Double-Blind Method | 4 | 2014 | 2064 | 0.170 |
Why?
| | Societies, Medical | 2 | 2025 | 901 | 0.170 |
Why?
| | Cell Count | 2 | 2015 | 315 | 0.170 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.160 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.160 |
Why?
| | Interleukin-6 | 3 | 2026 | 782 | 0.160 |
Why?
| | Feces | 1 | 2024 | 494 | 0.160 |
Why?
| | Neutrophils | 3 | 2017 | 1132 | 0.160 |
Why?
| | Phagocytosis | 2 | 2014 | 298 | 0.160 |
Why?
| | Physicians | 3 | 2022 | 954 | 0.160 |
Why?
| | Pandemics | 4 | 2022 | 1700 | 0.160 |
Why?
| | Random Allocation | 1 | 2021 | 365 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 673 | 0.160 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 333 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1652 | 0.150 |
Why?
| | Immunoglobulin A | 1 | 2021 | 205 | 0.150 |
Why?
| | Animals | 18 | 2025 | 38030 | 0.150 |
Why?
| | Permeability | 2 | 2012 | 166 | 0.150 |
Why?
| | Capacity Building | 1 | 2020 | 61 | 0.150 |
Why?
| | Chemokines | 2 | 2018 | 217 | 0.150 |
Why?
| | Career Choice | 2 | 2012 | 235 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1158 | 0.150 |
Why?
| | von Willebrand Factor | 1 | 2019 | 84 | 0.150 |
Why?
| | Homeostasis | 1 | 2003 | 646 | 0.140 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.140 |
Why?
| | Disaster Planning | 1 | 2020 | 109 | 0.140 |
Why?
| | Cardiology | 1 | 2022 | 363 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2022 | 305 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 68 | 0.140 |
Why?
| | Needs Assessment | 1 | 2021 | 403 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 952 | 0.140 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 423 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 8 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2436 | 0.140 |
Why?
| | Brain | 3 | 2021 | 2981 | 0.140 |
Why?
| | Wounds and Injuries | 1 | 2006 | 956 | 0.140 |
Why?
| | Pyridines | 2 | 2010 | 606 | 0.130 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 23 | 0.130 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 179 | 0.130 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 80 | 0.130 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 26 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 369 | 0.130 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 28 | 0.130 |
Why?
| | Length of Stay | 4 | 2020 | 1342 | 0.130 |
Why?
| | Cardiologists | 1 | 2018 | 45 | 0.130 |
Why?
| | Decision Making | 1 | 2025 | 987 | 0.130 |
Why?
| | Hospitals, University | 2 | 2015 | 176 | 0.130 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 112 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 246 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 110 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 960 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 973 | 0.120 |
Why?
| | Pyrazoles | 1 | 2001 | 516 | 0.120 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 466 | 0.120 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 166 | 0.120 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 194 | 0.120 |
Why?
| | Cystine | 1 | 2016 | 17 | 0.120 |
Why?
| | Interleukin-10 | 1 | 2018 | 310 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 543 | 0.120 |
Why?
| | Tobacco Use | 1 | 2017 | 67 | 0.120 |
Why?
| | Feasibility Studies | 3 | 2026 | 1125 | 0.120 |
Why?
| | Disulfides | 1 | 2016 | 93 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 824 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 319 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2022 | 11744 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4565 | 0.120 |
Why?
| | Teichoic Acids | 1 | 2016 | 21 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 767 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5397 | 0.110 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 178 | 0.110 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 302 | 0.110 |
Why?
| | RNA Splicing | 1 | 2017 | 287 | 0.110 |
Why?
| | Hospitalists | 1 | 2020 | 288 | 0.110 |
Why?
| | Proteins | 2 | 2021 | 1021 | 0.110 |
Why?
| | Inflammasomes | 1 | 2017 | 145 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 341 | 0.110 |
Why?
| | Hospitals | 1 | 2020 | 730 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 102 | 0.110 |
Why?
| | Patient Selection | 2 | 2023 | 720 | 0.110 |
Why?
| | Cysteine | 1 | 2016 | 210 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2017 | 249 | 0.110 |
Why?
| | Urinary Bladder | 1 | 2017 | 194 | 0.110 |
Why?
| | Cannabinoids | 1 | 2017 | 181 | 0.110 |
Why?
| | Acetylcysteine | 1 | 2016 | 139 | 0.110 |
Why?
| | Cholesterol | 1 | 2017 | 410 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 274 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 697 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5234 | 0.110 |
Why?
| | Prospective Studies | 7 | 2026 | 8087 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1075 | 0.100 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 158 | 0.100 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2910 | 0.100 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 61 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1269 | 0.100 |
Why?
| | Third-Party Consent | 1 | 2013 | 21 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1066 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 90 | 0.100 |
Why?
| | Competency-Based Education | 1 | 2014 | 82 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 40 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 29 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2357 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3396 | 0.090 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 44 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2017 | 410 | 0.090 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.090 |
Why?
| | Financial Support | 1 | 2012 | 18 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2857 | 0.090 |
Why?
| | Interleukin-12 | 1 | 2013 | 115 | 0.090 |
Why?
| | Logistic Models | 5 | 2017 | 2112 | 0.090 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 22 | 0.090 |
Why?
| | Aging | 2 | 2017 | 1983 | 0.090 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1429 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1325 | 0.090 |
Why?
| | Cell Survival | 1 | 2015 | 1102 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | Informed Consent | 1 | 2013 | 194 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 293 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 49 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1033 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 297 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 85 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 84 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 74 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 168 | 0.080 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3917 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 543 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 845 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 695 | 0.080 |
Why?
| | Capillaries | 2 | 2009 | 123 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 78 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1139 | 0.080 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.080 |
Why?
| | Genetic Testing | 1 | 2013 | 491 | 0.080 |
Why?
| | After-Hours Care | 1 | 2010 | 16 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 460 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 72 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 286 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1498 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 724 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 613 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 1979 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 159 | 0.070 |
Why?
| | Colorado | 5 | 2024 | 4588 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1581 | 0.070 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 232 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 365 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Peer Group | 1 | 2011 | 250 | 0.070 |
Why?
| | Mice | 7 | 2022 | 18266 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 424 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Computers | 1 | 2008 | 65 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1957 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 116 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6021 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 157 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 326 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 100 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 40 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 339 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 587 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2018 | 0.070 |
Why?
| | Schools | 1 | 2011 | 436 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 149 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 210 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.060 |
Why?
| | Cell Separation | 3 | 2016 | 300 | 0.060 |
Why?
| | Respiration Disorders | 1 | 2007 | 78 | 0.060 |
Why?
| | Indicators and Reagents | 1 | 2007 | 105 | 0.060 |
Why?
| | Georgia | 2 | 2004 | 79 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 132 | 0.060 |
Why?
| | Sex Factors | 1 | 2013 | 2101 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 458 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 146 | 0.060 |
Why?
| | Thrombocytopenia | 2 | 2019 | 205 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 413 | 0.060 |
Why?
| | Body Fluids | 1 | 2007 | 70 | 0.060 |
Why?
| | Program Evaluation | 1 | 2011 | 945 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1116 | 0.060 |
Why?
| | Patient Readmission | 3 | 2019 | 771 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 189 | 0.060 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 145 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 95 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 677 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5875 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 114 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 370 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 70 | 0.060 |
Why?
| | Neurofilament Proteins | 1 | 2025 | 83 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 124 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2013 | 2007 | 0.050 |
Why?
| | Louisiana | 1 | 2024 | 30 | 0.050 |
Why?
| | Observation | 1 | 2004 | 51 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 207 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22451 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 145 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 824 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1481 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2944 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6050 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 7079 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 344 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 33 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 24 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 74 | 0.040 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 76 | 0.040 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 59 | 0.040 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 77 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | North America | 1 | 2022 | 299 | 0.040 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.040 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 201 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 6 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 148 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 366 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 194 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 171 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 255 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3121 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 676 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 23 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 889 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1361 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5574 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 64 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 439 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2910 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1824 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4331 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 24 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 344 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 353 | 0.030 |
Why?
| | Coronary Circulation | 1 | 2018 | 134 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
| | Illinois | 1 | 2017 | 47 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 45 | 0.030 |
Why?
| | Leadership | 1 | 2022 | 410 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Phenotype | 1 | 2026 | 3186 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 140 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 170 | 0.030 |
Why?
| | Qualitative Research | 1 | 2025 | 1720 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 718 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 867 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1843 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 777 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 195 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1403 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 379 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3005 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 129 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 155 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 31 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2962 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 327 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 452 | 0.030 |
Why?
| | Risk | 1 | 2018 | 917 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 132 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 267 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 455 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 847 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 507 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 201 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 942 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 541 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 244 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 207 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 771 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1286 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2097 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 203 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 959 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 28 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.020 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2014 | 328 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 921 | 0.020 |
Why?
| | Ventilator Weaning | 1 | 2013 | 38 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1372 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.020 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.020 |
Why?
| | Thymus Gland | 1 | 2014 | 310 | 0.020 |
Why?
| | Tidal Volume | 1 | 2013 | 108 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 423 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 568 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 728 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 152 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 147 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 355 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 533 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 59 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2239 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2533 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 728 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 521 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 82 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 103 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 198 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 429 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 189 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 564 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1202 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 262 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 98 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 856 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 542 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1761 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 55 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 571 | 0.020 |
Why?
| | Amides | 1 | 2010 | 100 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 466 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 379 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1717 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 43 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 737 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1790 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 236 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1073 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 165 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 18 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 31 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 47 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 55 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 86 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 67 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 80 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 996 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 42 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 782 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 24 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 259 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 70 | 0.020 |
Why?
| | Child | 2 | 2022 | 22638 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 246 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 474 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 1074 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 511 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 950 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 355 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1758 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 235 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 533 | 0.010 |
Why?
| | Adipocytes | 1 | 2008 | 223 | 0.010 |
Why?
| | Trauma Centers | 1 | 2009 | 440 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 337 | 0.010 |
Why?
| | Cell Lineage | 1 | 2008 | 375 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1754 | 0.010 |
Why?
| | Chondrocytes | 1 | 2008 | 232 | 0.010 |
Why?
| | Telomerase | 1 | 2008 | 252 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 559 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1500 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 418 | 0.010 |
Why?
| | France | 1 | 2003 | 40 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 88 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 991 | 0.010 |
Why?
| | Washington | 1 | 2003 | 157 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 176 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2497 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1293 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|